What We're Reading: Page 174
Industry reads hand-picked by our editors
Dec 08, 2020
-
Reuters
'Go for it,' says grandmother who got world's first Pfizer COVID vaccine in Britain
-
Bloomberg
Palantir Wins FDA Contract to Power Drug Review, Inspections
-
The New York Times
AstraZeneca Vaccine Partner in China Dogged by Scandal
-
STAT
Divergent results from Agios, Forma trials for their sickle cell drugs
Dec 07, 2020
-
The Wall Street Journal
Watchdog for U.S. Agency That Brokered Controversial Kodak Loan Deal Finds No Wrongdoing
-
Evaluate Vantage
Bluebird’s early-stage sickle cell gene therapy shows promise
-
POLITICO
To rebuild CDC, Biden picks Rochelle Walensky
-
STAT
Kura's genetically targeted drug induces remission in AML patients
Dec 04, 2020
-
The Wall Street Journal
Dry Ice Demand Swells as Covid-19 Vaccines Prepare for Deployment
-
Endpoints News
BioCryst wins approval for HAE pill and charges half-a-million dollars, but will anyone take it?
-
Supply Chain Dive
FedEx will partner with McKesson on vaccine distribution, expand cold storage locations by 28% in 2021
-
Bloomberg
Bristol Myers Deal-Linked Derivative Surges on Inspection Hopes
Dec 03, 2020
-
The Wall Street Journal
FDA Head Defends Covid-19 Vaccine-Approval Process
-
FierceBiotech
Merck KGaA pens major cancer drugs biobucks pact with DNA damage biotech Artios Pharma
-
Vanity Fair
The COVID Vaccines Are Approaching. Is the FDA Ready to Inspect the Plants Where They're Made?
-
Endpoints News
Jazz's $1B SCLC drug fails combo trial, quashing hopes of quick full approval
Dec 02, 2020
-
Politico
Trump to FDA: Why is Europe beating us on vaccine?
-
The Wall Street Journal
Nasdaq Seeks Board-Diversity Rule That Most Listed Firms Don’t Meet
-
Reuters
AstraZeneca partner sticks with two full dose regimen in COVID trials in India
-
Bloomberg
Moderna Falls After Merck Sells Stake in the Vaccine Maker
Dec 01, 2020
Nov 30, 2020
-
STAT
The race to deliver CAR-T cancer therapy during the pandemic
-
Bloomberg
Astra Eyes Extra Global Vaccine Trial as Questions Mount
-
The New York Times
McKinsey Proposed Paying Pharmacy Companies Rebates for OxyContin Overdoses
-
Endpoints News
Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline
Previous
